Document:

EX-10.75

 Exhibit 10.75 

EXECUTIVE EMPLOYMENT 

AGREEMENT BY AND BETWEEN 

HORIZON PHARMA, INC., HORIZON PHARMA USA, INC. AND 

JOHN KODY 
 This Executive
Employment Agreement (hereinafter referred to as the “Agreement”), is entered into by and between Horizon Pharma, Inc., a Delaware corporation, and its wholly owned subsidiary, Horizon Pharma USA, Inc., a Delaware
corporation, each having a principal place of business at 520 Lake Cook Road, Suite 520, Deerfield, IL 60015, (hereinafter referred to together as the “Company”) and John Kody (hereinafter referred as to the
“Executive”). The terms of this Agreement shall remain confidential until the Executive’s first day of employment with the Company (the “Date of Hire”), which will be on November 24, 2014 and
which is also the effective date of this Agreement (the “Effective Date”) 
 RECITALS 

WHEREAS, Company desires assurance of the association and services of the Executive in order to retain the Executive’s experience,
skills, abilities, background and knowledge, and is willing to engage the Executive’s services on the terms and conditions set forth in this Agreement; and 

WHEREAS, Executive desires to be in the employ of the Company, and is willing to accept such employment on the terms and conditions set
forth in this Agreement. 
 AGREEMENT 
  

	1.	Employment. 

 1.1 Term. The Company hereby agrees to employ
the Executive, and the Executive hereby accepts employment by the Company, upon the terms and conditions set forth in this Agreement. Executive’s employment shall be governed under the terms set forth in this Agreement beginning on the
Effective Date and shall continue until it is terminated pursuant to Section 4 herein (hereinafter referred to as the “Term”). 

1.2 Title. The Executive shall have the title of Executive Vice President, Chief Commercial Officer of the Company (such
position held by Executive during such period is hereinafter referred to as “CCO”) and Executive shall serve in such other capacity or capacities commensurate with his position as CCO as the President and CEO of the Company
may from time to time prescribe. 
 1.3 Duties. The Executive shall do and perform all services, acts or things
necessary or advisable to manage and conduct the business of the Company and shall have the authority and responsibilities which are generally associated with the position of CCO including being responsible for the Company’s commercial strategy
and operations. The Executive shall report to the President and CEO. 

 1.4 Policies and Practices. The employment relationship between the
Parties shall be governed by this Agreement and the policies and practices established by the Company and the Board of Directors (hereinafter referred to as the “Board”). In the event that the terms of this Agreement differ
from or are in conflict with the Company’s policies or practices or the Company’s Employee Handbook, this Agreement shall control. 

1.5 Location. The Executive shall perform the services the Executive is required to perform pursuant to this Agreement
in the headquarters office for the Company in the Deerfield, Illinois area. The Company may from time to time require the Executive to travel temporarily to other locations outside of the Deerfield, Illinois area in connection with the
Company’s business. 
  

	2.	Loyalty of Executive. 

 2.1 Loyalty. During the
Executive’s employment by the Company, the Executive shall devote the Executive’s business energies, interest, abilities and productive time to the proper and efficient performance of Executive’s duties under this Agreement. Subject
to the prior written consent of the President and CEO, the Executive is permitted to serve on the board of directors of one other company, so long as the other company does not compete with the Company. 

2.2 Exclusive Employment. Except with the prior written consent of the Board, Executive shall not, during the term of
this Agreement, undertake or engage in any other employment, occupation or business enterprise, other than ones in which Executive is a passive investor. Executive may engage in any civic and not-for-profit activities so long as such activities do
not materially interfere with the performance of his duties hereunder or present a conflict of interest with the Company. 

2.3 Agreement not to Participate in Company’s Competitors. During the Term of this Agreement, the Executive agrees
not to acquire, assume or participate in, directly or indirectly, any position, investment or interest known by Executive to be adverse or antagonistic to the Company, its business or prospects, financial or otherwise or in any company, person or
entity that is, directly or indirectly, in competition with the business of the Company or any of its affiliates. Notwithstanding the foregoing, Executive may invest and/or maintain investments in any public or private entity up to an amount of 2%
of an entity’s fully diluted shares and on a passive basis. 

	3.	Compensation to Executive. 

 3.1 Base Salary. The Company
shall pay the Executive a base salary at the initial annualized rate of four hundred twenty seven thousand dollars ($427,000.00) per year, subject to standard deductions and withholdings, or such higher rate as may be determined from time to time by
the Board or the compensation committee thereof (hereinafter referred to as the “Base Salary”). Such Base Salary shall be paid in accordance with the Company’s standard payroll practice. Payments of salary installments
shall be made no less frequently than once per month. Executive’s Base Salary will be reviewed annually each December and Executive shall be eligible to receive a salary increase (but not decrease) annually in an amount to be determined by the
Board or the compensation committee thereof in its sole and exclusive discretion. Once increased, the new salary shall become the Base Salary for purposes of this Agreement and shall not be reduced without the Executive’s written consent. Any
material reduction in the Base Salary of the Executive, without his written consent, may be deemed Good Reason as set forth in and subject to Section 4.5.2 of this Agreement. 

3.2 Discretionary Bonus. Provided the Executive meets the conditions stated in this Section 3.2, the Executive
shall be eligible for an annual discretionary bonus (hereinafter referred to as the “Bonus”) with a target amount of fifty percent (50%) of the Executive’s Base Salary, subject to standard deductions and
withholdings, based on the Board’s determination, in good faith, and based upon the Executive’s individual achievement and company performance objectives as set by the Board or the compensation committee thereof, of whether the Executive
has met such performance milestones as are established for the Executive by the Board or the compensation committee thereof, in good faith, in consultation with the Executive (hereinafter referred to as the “Performance
Milestones”). The Performance Milestones will be based on certain factors including, but not limited to, the Executive’s performance and the Company’s financial performance. The Executive’s Bonus target will be reviewed
annually and may be adjusted by the Board or the compensation committee thereof in its discretion, provided however, that the Bonus target may only be materially reduced upon Executive’s written consent. The Executive must be employed on the
date the Bonus is awarded to be eligible for the Bonus, subject to the termination provisions thereof. The Bonus shall be paid during the calendar year following the performance calendar year. 

 3.3 Equity Awards. At the next scheduled Compensation Committee meeting
that follows the Date of Hire the Executive will be granted the following equity awards pursuant to and subject to the terms of the Company’s 2011 Equity Incentive Plan and its form of stock option and restricted stock unit award agreements, in
the forms provided to Executive concurrently with this Agreement (collectively the “Equity Plan Documents”) and compliance with applicable securities laws: 

3.3.1 New Hire Option. A stock option to purchase up to 128,000 shares of the Company’s common stock (the
“Option”). The Option will have an exercise price equal to the fair market value of the Company’s common stock on the applicable date of grant. Subject to Executive’s continued provision of services to the Company
through the applicable vesting dates, the Option shall vest as follows: 25% of the total number of shares subject to the Option shall vest on the first anniversary of the Date of Hire and 1/36 of the remaining number of shares subject to the Option
shall vest on each monthly anniversary thereafter so that the Option would fully vest on the four (4) year anniversary of the Date of Hire subject to Executive’s continued services with the Company through such date. 

3.3.2 New Hire Restricted Stock Unit Award. A restricted stock unit award in respect of 75,900 shares of the
Company’s common stock (the “RSU Award”). Subject to Executive’s continued provision of services to the Company through the applicable vesting dates, the RSU Award shall vest as follows: 25% of the total number of
units subject to the RSU Award shall vest on each anniversary of the Date of Hire so that the RSU Award would fully vest on the four (4) year anniversary of the Date of Hire subject to Executive’s continued services with the Company
through such date. 
 3.4 Sign-on Bonus. Within thirty (30) days of the Executive’s Date of Hire, Executive
will be paid a one-time bonus of one hundred fifty thousand dollars ($150,000.00) (the “Sign-on Bonus”), subject to standard deductions and withholdings. The Sign-on bonus is intended to compensate the Executive for the
annual bonus forfeited upon termination with his former company. If, prior to the first anniversary of the Date of Hire, Executive resigns for any reason other than for Good Reason, or the Company terminates his employment for Cause, Employee must
repay to the Company, on or within thirty (30) days after the employment termination date, an amount equal to the Sign-on Bonus. 

3.5 Legal Review. Upon the Executive’s submission of appropriate itemized proof and verification of reasonable and
customary legal fees incurred by the Executive in obtaining legal advice associated with the review, preparation, approval, and execution of this Agreement, the Company shall pay for up to $10,000.00 of such legal fees subject to receipt of
appropriate proof and verification of such legal fees no later than sixty (60) days of receipt of an invoice for legal services from the Executive and/or his attorneys. To be eligible for reimbursement, the invoice must be submitted no later
than ninety (90) days after the legal fees are incurred. 
 3.6 Changes to Compensation. The Executive’s
compensation may be changed from time to time by mutual agreement of the Executive and the Company. In the event that the Executive’s base salary is materially decreased without his written consent, said decrease will be Good Reason for the
Executive to terminate the Agreement as set forth in and subject to Section 4.5.2 of this Agreement. 

 3.7 Taxes. All amounts paid under this Agreement to the Executive by the
Company will be paid less applicable tax withholdings and any other withholdings required by law or authorized by the Executive. 

3.8 Benefits. The Executive shall, in accordance with Company policy and the terms of the applicable plan documents, be
eligible to participate in benefits under any executive benefit plan or arrangement which may be in effect from time to time and made available to the Company’s executives or key management employees, provided, however, that the Executive shall
be entitled to at least four (4) weeks of paid vacation annually. 
 3.9 Vidara Transaction Section 4985
Gross-Up. To the extent that the Company agrees to reimburse any of the executive officers of the Company for any excise tax imposed upon them pursuant to Section 4985 of the Code in connection with the Company’s proposed strategic
transaction with Vidara Therapeutics International Ltd., including any reimbursement for income taxes imposed upon such excise tax reimbursement, the Executive shall be entitled to be reimbursed on the same basis as the other executive officers.

  

	4.	Termination. 

 4.1 Termination by the Company. The
Executive’s employment with the Company may be terminated only under the following conditions: 
 4.1.1 Termination
for Death or Disability. The Executive’s employment with the Company shall terminate effective upon the date of the Executive’s death or “Complete Disability” (as defined in Section 4.5.1), provided,
however, that this Section 4.1.1 shall in no way limit the Company’s obligations to provide such reasonable accommodations to the Executive and/or his heirs as may be required by law. 

4.1.2 Termination by the Company For Cause. The Company may terminate the Executive’s employment under this
Agreement for “Cause” (as defined in Section 4.5.3) by delivery of written notice to the Executive specifying the Cause or Causes relied upon for such termination, provided that such notice is delivered within two
(2) months following the occurrence or discovery of any event or events constituting “Cause”. Any notice of termination given pursuant to this Section 4.1.2 shall effect termination as of the date of the notice or
such date as specified in the notice. The Executive shall have the right to appear before the CEO before any termination for Cause becomes effective and binding upon the Executive. 

4.1.3 Termination by the Company Without Cause. The Company may terminate the Executive’s employment under this
Agreement at any time and for any reason or no reason subject to the requirements set out in Section 4.4 of this Agreement. Such termination shall be effective on the date the Executive is so informed or as otherwise specified by the Company,
pursuant to notice requirements set forth in Section 6 of this Agreement. 

 4.2 Termination By The Executive. The Executive may terminate his
employment with the Company at any time and for any reason or no reason, including, but not limited, to the following conditions: 

4.2.1 Good Reason. The Executive may terminate his employment under this Agreement for “Good
Reason” (as defined below in Section 4.5.2) by delivery of written notice to the Company specifying the Good Reason relied upon by the Executive for such termination in accordance with the requirements of such section. 

4.2.2 Without Good Reason. The Executive may terminate the Executive’s employment hereunder for other than Good
Reason upon thirty (30) days written notice to the Company. 
 4.3 Termination by Mutual Agreement of the
Parties. The Executive’s employment pursuant to this Agreement may be terminated at any time upon a mutual agreement in writing of the Parties. Any such termination of employment shall have the consequences specified in such mutual
agreement. 
 4.4 Compensation to Executive Upon Termination. In connection with any termination of the
Executive’s employment for any reason, the Executive or the Executive’s estate, as applicable, shall be entitled to any amounts payable to the Executive or the Executive’s beneficiaries subject to and accordance with the terms of the
Company’s employee welfare benefit plans or policies (excluding any severance pay). 
 4.4.1 Death or Complete
Disability. If the Executive’s employment shall be terminated by death or Complete Disability as provided in Section 4.1.1, the Company shall pay to Executive, and/or Executive’s heirs, all earned but unpaid Base Salary, any
earned but unpaid discretionary bonuses for any prior period at such time as bonuses would have been paid if the Executive remained employed, all accrued but unpaid business expenses, and all accrued but unused vacation time earned through the date
of termination at the rate in effect at the time of termination (hereinafter referred to as the “Accrued Amounts”), less standard deductions and withholdings. The Executive shall also be eligible to receive a pro-rated bonus
for the year of termination, as determined by the Board or the Compensation Committee of the Board based on actual performance and the period of the year he was employed (hereinafter referred to as the “Pro-rata Bonus”), less
standard deductions and withholdings, to be paid as a lump sum within thirty (30) days after the date of termination. 

4.4.2 With Cause or Without Good Reason. If the Executive’s employment shall be terminated by the Company for
Cause, or if the Executive terminates employment hereunder without Good Reason, the Company shall pay the Executive’s Base Salary, accrued but unpaid business expenses and accrued and unused vacation benefits earned through the date of
termination at the rate in effect at the time of termination, less standard deductions and withholdings. 

 4.4.3 Without Cause or For Good Reason. 

(i) Not in Connection With a Change in Control. If the Company terminates the Executive’s employment without Cause
or the Executive terminates his employment for Good Reason, and Section 4.4.3(ii) below does not apply, the Company shall pay the Accrued Amounts subject to standard deductions and withholdings, to be paid as a lump sum no later than thirty
(30) days after the date of termination. In addition, subject to the limitations stated in this Agreement and upon the Executive’s furnishing to the Company an executed waiver and release of claims (the form of which is attached hereto as
Exhibit A) (the “Release”) within the applicable time period set forth therein, but in no event later than forty-five days following termination of employment and permitting such Release to become effective in accordance with
its terms (the “Release Effective Date”), and subject to Executive entering into no later than the Release Effective Date a non-competition agreement to be effective during the Severance Period (as defined below),
substantially similar to Section 2.3, and continuing to abide by its terms during the Severance Period, the Executive shall be entitled to: 

(a) the equivalent of the Executive’s Base Salary in effect at the time of termination will continue to be paid
for a period of twelve (12) months following the date of termination (hereinafter referred to as the “Severance Period”), less standard deductions and withholdings, to be paid during the Severance Period according to the
Company’s regular payroll practices, subject to any delay in payment required by Section 4.6 in connection with the Release Effective Date; and 

(b) in the event the Executive timely elects continued coverage under COBRA, the Company will continue to pay the same
portion of Executive’s COBRA health insurance premium as the percentage of health insurance premiums that it paid during the Executive’s employment, including any amounts that Company paid for benefits to the qualifying family members of
the Executive, following the date of termination up until the earlier of either (i) the last day of the Severance Period or, (ii) the date on which the Executive begins full-time employment with another company or business entity which
offers comparable health insurance coverage to the Executive (such period, the “COBRA Payment Period”). Notwithstanding the foregoing, if the Company determines, in its sole discretion, that the Company cannot provide the
COBRA premium benefits without potentially incurring financial costs or penalties under applicable law (including, without limitation, Section 2716 of the Public Health Service Act), the Company shall in lieu thereof pay Executive a taxable
cash amount, which payment shall be made regardless of whether the Executive or his qualifying family members elect COBRA continuation coverage (the “Health Care Benefit Payment”). The Health Care Benefit Payment shall be
paid in monthly or bi-weekly installments on the same schedule that the COBRA premiums would otherwise have been paid to the insurer. The Health Care Benefit Payment shall be equal to the amount that the Company otherwise would have paid for COBRA
insurance premiums (which amount shall be calculated based on the premium for the first month of coverage), and shall be paid until the expiration of the COBRA Payment Period. 

 (ii) In Connection With a Change in Control. If the Company (or its
successor) terminates the Executive’s employment without Cause or the Executive terminates his employment for Good Reason within the period commencing ninety (90) days immediately prior to a Change in Control of the Company and ending
eighteen (18) months immediately following a Change in Control of the Company (as defined in Section 4.5.4 of this Agreement), the Executive shall receive the Accrued Amounts subject to standard deductions and withholdings, to be paid as a
lump sum no later than thirty (30) days after the date of termination. In addition, subject to the limitations stated in this Agreement and upon the Executive’s furnishing to the Company (or its successor) an executed Release within the
applicable time period set forth therein, but in no event later than forty-five days following termination of employment and permitting such Release to become effective in accordance with its terms, and subject to Executive entering into no later
than the Release Effective Date a non-competition agreement to be effective during the Severance Period, substantially similar to Section 2.3, and continuing to abide by its terms during the Severance Period, then in lieu of (and not additional
to) the benefits provided pursuant to Section 4.4.3(i) above, the Executive shall be entitled to: 
 (a) the
equivalent of the Executive’s Base Salary in effect at the time of termination will continue to be paid during the Severance Period, less standard deductions and withholdings, to be paid during the Severance Period according to the
Company’s regular payroll practices, subject to any delay in payment required by Section 4.6 in connection with the Release Effective Date; 

(b) Executive’s target Bonus in effect at the time of termination, or if none, the last target Bonus in effect for
Executive, less standard deductions and withholdings, to be paid in a lump sum within ten (10) days following the later of (i) the Release Effective Date, or (ii) the effective date of the Change in Control; and 

(c) in the event the Executive timely elects continued coverage under COBRA, the Company will continue to pay the same
portion of Executive’s COBRA health insurance premium as the percentage of health insurance premiums that it paid during the Executive’s employment, including any amounts that Company paid for benefits to the qualifying family members of
the Executive, following the date of termination until the expiration of the COBRA Payment Period. Notwithstanding the foregoing, if the Company determines, in its sole discretion, that the Company cannot provide the COBRA premium benefits without
potentially incurring financial costs or penalties under applicable law (including, without limitation, Section 2716 of the Public Health Service Act), the Company shall in lieu thereof pay Executive the Health Care Benefit Payment, which
payment shall be made regardless of whether the Executive or his qualifying family members elect COBRA continuation coverage. The Health Care Benefit Payment shall be paid in monthly or bi-weekly installments on the same schedule that the COBRA
premiums would otherwise have been paid to the insurer. The Health Care Benefit Payment shall be equal to the amount that the Company otherwise would have paid for COBRA insurance premiums (which amount shall be calculated based on the premium for
the first month of coverage), and shall be paid until the expiration of the COBRA Payment Period. 

 (iii) No Duplication of Benefits. For the avoidance of doubt, in no event
will Executive be entitled to benefits under Section 4.4.3(i) and Section 4.4.3(ii). If Executive commences to receive benefits under Section 4.4.3(i) due to a qualifying termination prior to a Change in Control and thereafter becomes
entitled to benefits under Section 4.4.3(ii), any benefits previously provided to Executive under Section 4.4.3(i) shall offset the benefits to be provided to Executive under Section 4.4.3(ii) and shall be deemed to have been provided
to Executive pursuant to Section 4.4.3(ii). 
 4.4.4 Equity Award Acceleration. 

(i) In Connection With a Change in Control. In the event that the Executive’s employment is terminated without
Cause or for Good Reason within the ninety (90) days immediately preceding or during the eighteen (18) months immediately following a Change in Control of the Company (as defined in Section 4.5.4 of this Agreement), the vesting of the
Option, the RSU Award and any other Company equity awards granted to Executive shall be fully accelerated such that on the effective date of such termination (or, if later, the date of the Change in Control) one hundred percent (100%) of the
equity award shares granted to Executive prior to such termination shall be fully vested and immediately exercisable, if applicable, by the Executive. 

(ii) Release and Waiver. Any equity vesting acceleration pursuant to this Section 4.4.4 shall be conditioned upon
and subject to the Executive’s delivery to the Company of a fully effective Release in accordance with the terms specified by Section 4.4.3 hereof and such vesting acceleration benefit shall be in addition to the benefits provided by
Section 4.4.3 hereof 
 4.5 Definitions. For purposes of this Agreement, the following terms shall have
the following meanings: 
 4.5.1 Complete Disability. “Complete Disability” shall mean
the inability of the Executive to perform the Executive’s duties under this Agreement, whether with or without reasonable accommodation, because the Executive has become permanently disabled within the meaning of any policy of disability income
insurance covering employees of the Company then in force. In the event the Company has no policy of disability income insurance covering employees of the Company in force when the Executive becomes disabled, the term “Complete
Disability” shall mean the inability of the Executive to perform the Executive’s duties under this Agreement, whether with or without reasonable accommodation, by reason of any incapacity, physical or mental, which the Board, based
upon medical advice or an opinion provided by a licensed physician, determines to have incapacitated the Executive from satisfactorily performing all of the Executive’s usual services for the Company, with or without reasonable accommodation,
for a period of at least one hundred eighty (180) days during any twelve (12) month period that need not be consecutive. 

 4.5.2 Good Reason. “Good Reason” for the Executive
to terminate the Executive’s employment hereunder shall mean the occurrence of any of the following events without the Executive’s consent: 

(i) a material reduction in the Executive’s duties, authority, or responsibilities relative to the duties,
authority, or responsibilities in effect immediately prior to such reduction, including by way of example, having the same title, duties, authority and responsibilities at a subsidiary level following a Change in Control; 

(ii) the relocation of the Executive’s primary work location to a point more than fifty (50) miles from the
Executive’s current work location set forth in Section 1.5 that requires a material increase in Executive’s one-way driving distance; 

(iii) a material reduction by the Company of the Executive’s base salary or annual target Bonus opportunity,
without the written consent of the Executive, as initially set forth herein or as the same may be increased from time to time pursuant to this Agreement; and 

(iv) a material breach by the Company of Section 1.2 of this Agreement. 

Provided, however that, such termination by the Executive shall only be deemed for Good Reason pursuant to the foregoing definition if (i) the Company is
given written notice from the Executive within sixty (60) days following the first occurrence of the condition that he considers to constitute Good Reason describing the condition and the Company fails to satisfactorily remedy such condition
within thirty (30) days following such written notice, and (ii) the Executive terminates employment within thirty (30) days following the end of the period within which the Company was entitled to remedy the condition constituting
Good Reason but failed to do so. 
 4.5.3 Cause. “Cause” for the Company to terminate
Executive’s employment hereunder shall mean the occurrence of any of the following events, as determined reasonably and in good faith by the Board or a committee designated by the Board: 

(i) the Executive’s gross negligence or willful failure to substantially perform his duties and responsibilities
to the Company or willful and deliberate violation of a Company policy; 
 (ii) the Executive’s conviction of a
felony or the Executive’s commission of any act of fraud, embezzlement or dishonesty against the Company or involving moral turpitude that is likely to inflict or has inflicted material injury on the business of the Company, to be determined by
the sole discretion of the Company; 
 (iii) the Executive’s unauthorized use or disclosure of any proprietary
information or trade secrets of the Company or any other party that the Executive owes an obligation of nondisclosure as a result of the Executive’s relationship with the Company; and 

 (iv) the Executive’s willful and deliberate breach of the
obligations under this Agreement that causes material injury to the business of the Company. 
 4.5.4 Change in
Control. For purposes of this Agreement, “Change in Control” means: (i) a sale of all or substantially all of the assets of the Company; (ii) a merger or consolidation in which the Company is not the surviving
entity and in which the holders of the Company’s outstanding voting stock immediately prior to such transaction own, immediately after such transaction, securities representing less than fifty percent (50%) of the voting power of the
entity surviving such transaction or, where the surviving entity is a wholly-owned subsidiary of another entity, the surviving entity’s parent; (iii) a reverse merger in which the Company is the surviving entity but the shares of Common
Stock outstanding immediately preceding the merger are converted by virtue of the merger into other property, whether in the form of securities of the surviving entity’s parent, cash or otherwise, and in which the holders of the Company’s
outstanding voting stock immediately prior to such transaction own, immediately after such transaction, securities representing less than fifty percent (50%) of the voting power of the Company or, where the Company is a wholly-owned subsidiary
of another entity, the Company’s parent; or (iv) an acquisition by any person, entity or group (excluding any employee benefit plan, or related trust, sponsored or maintained by the Company or subsidiary of the Company or other entity
controlled by the Company) of the beneficial ownership of securities of the Company representing at least seventy-five percent (75%) of the combined voting power entitled to vote in the election of Directors; provided, however, that nothing in
this paragraph shall apply to a sale of assets, merger or other transaction effected exclusively for the purpose of changing the domicile of the Company. 

4.6 Application of Internal Revenue Code Section 409A. Notwithstanding anything to the contrary set forth herein,
any payments and benefits provided under this Agreement (the “Severance Benefits”) that constitute “deferred compensation” within the meaning of Section 409A of the Internal Revenue Code of 1986,
as amended (the “Code”) and the regulations and other guidance thereunder and any state law of similar effect (collectively “Section 409A”) shall not commence in connection with Executive’s
termination of employment unless and until Executive has also incurred a “separation from service” (as such term is defined in Treasury Regulation Section 1.409A-1(h) (“Separation From Service”), unless the
Company reasonably determines that such amounts may be provided to Executive without causing Executive to incur the additional 20% tax under Section 409A. 

It is intended that each installment of the Severance Benefits payments provided for in this Agreement is a separate
“payment” for purposes of Treasury Regulation Section 1.409A-2(b)(2)(i). For the avoidance of doubt, it is intended that payments of the Severance Benefits set forth in this Agreement satisfy, to the greatest extent
possible, the exemptions from the application of Section 409A provided under Treasury Regulation Sections 1.409A-1(b)(4), 1.409A-1(b)(5) and 1.409A-1(b)(9). However, if the Company 

 
(or, if applicable, the successor entity thereto) determines that the Severance Benefits constitute “deferred compensation” under Section 409A and Executive is, on
the termination of service, a “specified employee” of the Company or any successor entity thereto, as such term is defined in Section 409A(a)(2)(B)(i) of the Code, then, solely to the extent necessary to avoid the
incurrence of the adverse personal tax consequences under Section 409A, the timing of the Severance Benefit payments shall be delayed until the earlier to occur of (i) the date that is six months and one day after Executive’s
Separation From Service, or (ii) the date of Executive’s death (such applicable date, the “Specified Employee Initial Payment Date”), the Company (or the successor entity thereto, as applicable) shall (A) pay
to Executive a lump sum amount equal to the sum of the Severance Benefit payments that Executive would otherwise have received through the Specified Employee Initial Payment Date if the commencement of the payment of the Severance Benefits had not
been so delayed pursuant to this Section and (B) commence paying the balance of the Severance Benefits in accordance with the applicable payment schedules set forth in this Agreement. 

Notwithstanding anything to the contrary set forth herein, Executive shall receive the Severance Benefits described above, if and only if
Executive duly executes and returns to the Company within the applicable time period set forth therein, but in no event more than forty-five days following Separation From Service, the Company’s standard form of release of claims in favor of
the Company (attached to this Agreement as Exhibit A) (the “Release”) and permits the release of claims contained therein to become effective in accordance with its terms (such latest permitted date, the “Release
Deadline”). If the severance benefits are not covered by one or more exemptions from the application of Section 409A and the Release could become effective in the calendar year following the calendar year in which Executive
separates from service, the Release will not be deemed effective any earlier than the Release Deadline. Notwithstanding any other payment schedule set forth in this Agreement, none of the Severance Benefits will be paid or otherwise delivered prior
to the effective date (or deemed effective date) of the Release. Except to the extent that payments may be delayed until the Specified Employee Initial Payment Date pursuant to the preceding paragraph, on the first regular payroll pay day following
the effective date of the Release, the Company will pay Executive the Severance Benefits Executive would otherwise have received under the Agreement on or prior to such date but for the delay in payment related to the effectiveness of the Release,
with the balance of the Severance Benefits being paid as originally scheduled. 
 The severance benefits are intended to qualify for an
exemption from application of Section 409A or comply with its requirements to the extent necessary to avoid adverse personal tax consequences under Section 409A, and any ambiguities herein shall be interpreted accordingly. 

4.7 Application of Internal Revenue Code Section 280G. If any payment or benefit Executive would receive pursuant
to a Change in Control rom the Company or otherwise (“Payment”) would (i) constitute a “parachute payment” within the meaning of Section 280G of the Code, and (ii) but for this sentence,
be subject to the excise tax imposed by Section 4999 

 
of the Code (the “Excise Tax”), then such Payment shall be equal to the Reduced Amount. The “Reduced Amount” shall be either (x) the largest
portion of the Payment that would result in no portion of the Payment being subject to the Excise Tax or (y) the largest portion, up to and including the total, of the Payment, whichever amount, after taking into account all applicable federal,
state and local employment taxes, income taxes, and the Excise Tax (all computed at the highest applicable marginal rate), results in Executive’s receipt, on an after-tax basis, of the greater economic benefit notwithstanding that all or some
portion of the Payment may be subject to the Excise Tax. If a reduction in payments or benefits constituting “parachute payments” is necessary so that the Payment equals the Reduced Amount, reduction shall occur in the manner that results
in the greatest economic benefit for Executive. If more than one method of reduction will result in the same economic benefit, the items so reduced will be reduced pro rata. 

In the event it is subsequently determined by the Internal Revenue Service that some portion of the Reduced Amount as determined pursuant to
clause (x) in the preceding paragraph is subject to the Excise Tax, Executive agrees to promptly return to the Company a sufficient amount of the Payment so that no portion of the Reduced Amount is subject to the Excise Tax. For the avoidance
of doubt, if the Reduced Amount is determined pursuant to clause (y) in the preceding paragraph, Executive will have no obligation to return any portion of the Payment pursuant to the preceding sentence. 

Unless Executive and the Company agree on an alternative accounting firm, the accounting firm engaged by the Company for general tax
compliance purposes as of the day prior to the effective date of the Change in Control shall perform the foregoing calculations. If the accounting firm so engaged by the Company is serving as accountant or auditor for the individual, entity or group
effecting the Change in Control, the Company shall appoint a nationally recognized accounting firm to make the determinations required hereunder. The Company shall bear all expenses with respect to the determinations by such accounting firm required
to be made hereunder. 
 The Company shall use commercially reasonable efforts to cause the accounting firm engaged to make the
determinations hereunder to provide its calculations, together with detailed supporting documentation, to Executive and the Company within fifteen (15) calendar days after the date on which Executive’s right to a Payment is triggered (if
requested at that time by Executive or the Company) or such other time as requested by Executive or the Company. 
 4.8
Indemnification Agreement. Concurrently with the execution of this Agreement, the Company and the Executive shall enter into an indemnification agreement, a copy of which is attached hereto as Exhibit B. 

4.9 Confidential Information and Invention Assignment Agreement. Concurrently with the execution of this Agreement, the
Executive shall execute the Company’s Confidential Information and Invention Assignment Agreement, a copy of which is attached as Exhibit C. 

 4.10 No Mitigation or Offset. The Executive shall not be required to seek
or accept other employment, or otherwise to mitigate damages, as a condition to receipt of the Severance Benefits, and the Severance Benefits shall not be offset by any amounts received by the Executive from any other source, except to the extent
that the Executive’s right the benefits described in Sections 4.4.3(i)(b) or 4.4.3(ii)(c), as applicable, are terminated by reason of the Executive obtaining full-time employment with another company or business entity which offers comparable
health insurance coverage. 
  

	5.	Assignment and Binding Effect.  

 This Agreement shall be binding upon the
Executive and the Company and inure to the benefit of the Executive and the Executive’s heirs, executors, personal representatives, assigns, administrators and legal representatives. Because of the unique and personal nature of the
Executive’s duties under this Agreement, neither this Agreement nor obligations under this Agreement shall be assignable by the Executive. This Agreement shall be binding upon and inure to the benefit of the Company and its successors, assigns
and legal representatives, provided that the Agreement may only be assigned to an acquirer of all or substantially all of the Company’s assets. Any such successor of the Company will be deemed substituted for the Company under the terms of this
Agreement for all purposes. For this purpose, “successor” means any person, firm, corporation or other business entity which at any time, whether by purchase, merger or otherwise, directly or indirectly acquires all or substantially all of
the assets or business of the Company. 
  

	6.	Notice. 

 For the purposes of this Agreement, notices, demands, and all other
forms of communication provided for in this Agreement shall be in writing and shall be deemed to have been duly given when delivered or (unless otherwise specified) mailed by registered mail, return receipt requested, postage prepaid, or by
confirmed facsimile, addressed as set forth below, or to such other address as any party may have furnished to the other in writing in accordance herewith, except that notices of address shall be effective only upon receipt, as follows: 

If to the Company: 
 Horizon
Pharma, Inc. 
 520 Lake Cook Road, Suite 520 

Deerfield, IL 60015 
 Attention:
Timothy P. Walbert, Chairman, President & CEO 
 Fax: 847-572-1372 

If to the Executive: 
 John Kody

 330 Brampton Court 
 Lake
Forest, IL 60045 

 Any such written notice shall be deemed given on the earlier of the date on which such notice is personally
delivered or five (5) days after its deposit in the United States mail as specified above. Either Party may change its address for notices by giving written notice to the other Party in the manner specified in this section. 

 

	7.	Choice of Law. 

 This Agreement shall be governed by the laws of the State of
Illinois, without regard to any conflicts of law principals thereof that would call for the application of the laws of any other jurisdiction. The Parties consent to the exclusive jurisdiction and venue of the federal court in the Northern District
of Illinois, and state courts located in the state of Illinois, county of Cook. Nothing in this Section 7 limits the rights of the Parties to seek appeal of a decision of an Illinois court outside of Illinois that has proper jurisdiction over
the decision of a court sitting in Illinois. 
  

	8.	Integration. 

 This Agreement, including Exhibit A, Exhibit B, Exhibit C and the
Equity Plan Documents, contains the complete, final and exclusive agreement of the Parties relating to the terms and conditions of the Executive’s employment and the termination of Executive’s employment, and supersedes all prior and
contemporaneous oral and written employment agreements or arrangements between the Parties. 
  

	9.	Amendment. 

 This Agreement cannot be amended or modified except by a written
agreement signed by the Executive and the Company. 
  

	10.	Waiver. 

 No term, covenant or condition of this Agreement or any breach thereof
shall be deemed waived, except with the written consent of the Party against whom the wavier is claimed, and any waiver or any such term, covenant, condition or breach shall not be deemed to be a waiver of any preceding or succeeding breach of the
same or any other term, covenant, condition or breach. 
  

	11.	Severability. 

 The finding by a court of competent jurisdiction of the
unenforceability, invalidity or illegality of any provision of this Agreement shall not render any other provision of this Agreement unenforceable, invalid or illegal. Such court shall have the authority to modify or replace the invalid or
unenforceable term or provision with a valid and enforceable term or provision, which most accurately represents the Parties’ intention with respect to the invalid, unenforceable, or illegal term or provision. 

	12.	Interpretation; Construction. 

 The headings set forth in this Agreement are for
convenience of reference only and shall not be used in interpreting this Agreement. This Agreement has been drafted and negotiated by legal counsel representing the Company and the Executive. The Parties acknowledge that each Party and its counsel
has reviewed and revised, or had an opportunity to review and revise, this Agreement, and any rule of construction to the effect that any ambiguities are to be resolved against the drafting party shall not be employed in the interpretation of this
Agreement. 
  

	13.	Execution by Facsimile Signatures and in Counterparts. 

 The parties agree that
facsimile signatures shall have the same force and effect as original signatures. This Agreement may be executed in one or more counterparts, each of which shall be deemed an original but all of which together shall constitute one and the same
instrument. 
  

	14.	Survival. 

 The provisions of this Agreement, and of all other agreements
referenced herein, shall survive the termination of this Agreement, and of the Executive’s employment by the Company for any reason, to the extent necessary to enable the parties to enforce their respective rights hereunder. 

[Remainder of Page Intentionally Left Blank] 

 IN WITNESS WHEREFORE, the parties have signed this Agreement on the date first written
above. 
  

			
	COMPANY:
	
	 HORIZON PHARMA, INC.

HORIZON PHARMA USA, INC.

	
	By:
		
	Title:		Chairman, President & CEO

			
		
	Print Name:		Timothy P. Walbert

			
	
	/s/ Timothy P. Walbert

 Signature: 
 As
authorized agent of the Company 

	
	
	October 30, 2014
	Date

  

	
	EXECUTIVE:
	
	John Kody
	
	/s/ John Kody
	John Kody, individually
	
	October 30, 2014
	Date

 EXHIBIT A 

RELEASE AND WAIVER OF CLAIMS 

In consideration of the payments and other benefits set forth in Section 4.4 of the Executive Employment Agreement dated
             2014, (the “Employment Agreement”), to which this form is attached, I, John Kody, hereby furnish Horizon Pharma, Inc. and Horizon Pharma USA, Inc.
(together the “Company”), with the following release and waiver (“Release and Waiver”). 

In exchange for the consideration provided to me by the Employment Agreement that I am not otherwise entitled to receive, I
hereby generally and completely release the Company and its directors, officers, employees, shareholders, partners, agents, attorneys, predecessors, successors, parent and subsidiary entities, insurers, Affiliates, and assigns from any and all
claims, liabilities and obligations, both known and unknown, that arise out of or are in any way related to events, acts, conduct, or omissions occurring relating to my employment or the termination thereof prior to my signing this Release and
Waiver. This general release includes, but is not limited to: (1) all claims arising out of or in any way related to my employment with the Company or the termination of that employment; (2) all claims related to my compensation or
benefits from the Company, including, but not limited to, salary, bonuses, commissions, vacation pay, expense reimbursements, severance pay, fringe benefits, stock, stock options, or any other ownership interests in the Company; (3) all claims
for breach of contract, wrongful termination, and breach of the implied covenant of good faith and fair dealing; (4) all tort claims, including, but not limited to, claims for fraud, defamation, emotional distress, and discharge in violation of
public policy; and (5) all federal, state, and local statutory claims, including, but not limited to, claims for discrimination, harassment, retaliation, attorneys’ fees, or other claims arising under the federal Civil Rights Act of 1964
(as amended), the federal Americans with Disabilities Act of 1990, the federal Age Discrimination in Employment Act of 1967 (as amended) (“ADEA”), the Illinois Human Rights Act, the Illinois Equal Pay Act, the Illinois
Religious Freedom Restoration Act, and the Illinois Genetic Information Privacy Act. Notwithstanding the foregoing, this Release and Waiver, shall not release or waive my rights: to indemnification under the articles and bylaws of the Company or
applicable law; to payments under Sections                      of the Employment Agreement; under any provision of the Employment Agreement
that survives the termination of that agreement; under any applicable workers’ compensation statute; under any option, restricted share or other agreement concerning any equity interest in the Company; as a shareholder of the Company or any
other right that is not waivable under applicable law. 
 I acknowledge that, among other rights, I am waiving and releasing
any rights I may have under ADEA, that this Release and Waiver is knowing and voluntary, and that the consideration given for this Release and Waiver is in addition to anything of value to which I was already entitled as an executive of the Company.
If I am 40 years of age or older upon execution of this Release and Waiver, I further acknowledge that I have been advised, as required by the Older Workers Benefit Protection Act, that: (a) the release

 
and waiver granted herein does not relate to claims under the ADEA which may arise after this Release and Waiver is executed; (b) I should consult with an attorney prior to executing this
Release and Waiver; and (c) I have twenty-one (21) days from the date of termination of my employment with the Company in which to consider this Release and Waiver (although I may choose voluntarily to execute this Release and Waiver
earlier); (d) I have seven (7) days following the execution of this Release and Waiver to revoke my consent to this Release and Waiver; and (e) this Release and Waiver shall not be effective until the seven (7) day revocation
period has expired unexercised. If I am less than 40 years of age upon execution of this Release and Waiver, I acknowledge that I have the right to consult with an attorney prior to executing this Release and Waiver (although I may choose
voluntarily not to do so); and (c) I have five (5) days from the date of termination of my employment with the Company in which to consider this Release and Waiver (although I may choose voluntarily to execute this Release and Waiver
earlier). 
 I acknowledge my continuing obligations under my Confidential Information and Inventions Agreement dated
                    , 2014. Pursuant to the Confidential Information and Inventions Agreement I understand that among other things, I must not
use or disclose any confidential or proprietary information of the Company and I must immediately return all Company property and documents (including all embodiments of proprietary information) and all copies thereof in my possession or control. I
understand and agree that my right to the payments and other benefits I am receiving in exchange for my agreement to the terms of this Release and Waiver is contingent upon my continued compliance with my Confidential Information and Inventions
Agreement. 
 This Release and Waiver, including my Confidential Information and Inventions Agreement dated
                    , 2014, constitutes the complete, final and exclusive embodiment of the entire agreement between the Company and me with
regard to the subject matter hereof. I am not relying on any promise or representation by the Company that is not expressly stated herein. This Release and Waiver may only be modified by a writing signed by both me and a duly authorized officer of
the Company. 
  

			
	Date:		
		
	By:		
			John KodyEX-10.76

 Exhibit 10.76 
  

 
 HORIZON PHARMA PUBLIC LIMITED
COMPANY 
 CASH LONG TERM INCENTIVE PROGRAM

 EFFECTIVE DATE: NOVEMBER 5, 2014 

1. Purpose. The Horizon Pharma Public Limited Company Cash Long Term Incentive Program (the “Program”) is for
purposes of providing cash incentive compensation to individuals who make a significant contribution to the performance of Horizon Pharma Public Limited Company (the “Company”) and its Affiliates and who are selected for
participation in the Program (the “Designated Participants”). The Program objectives are to: (a) provide additional motivation to the Designated Participants to focus on our long-term corporate performance,
(b) provide an additional retention incentive for Designated Participants, and (c) further align the interests of the Designated Participants with those of our shareholders. Defined terms not explicitly defined in this Program document
including its attached APPENDIX A but defined in the Equity Incentive Plan will have the same definitions as in the Equity Incentive Plan. 

2. How Awards Are Earned Under the Program. 

(a) General Program Description. The Program provides the opportunity for the Designated Participants to
earn a cash bonus based on the Company’s level of attainment of performance goals as specified below in Section 2(d) (the “Performance Goals”) during the period of time that begins on November 5, 2014 and ends
on November 4, 2017 (the “Performance Period”). If the Performance Goals are not achieved during the Performance Period, the Designated Participants will not earn any cash bonus under the Program. To the maximum extent
possible, payments made under the Program are intended to qualify as “Performance Cash Awards” under the Equity Incentive Plan. 

(b) Maximum Award; Actual Award. The maximum cash bonus that a Designated Participant is eligible to earn
under the Program will in no event exceed his or her maximum award amount specified on the attached APPENDIX B under the “TSR Level 60%” column next to the name of such Designated Participant (the “Maximum
Award”). The Actual Award earned by and payable to each Participant under the Program will be determined by the Committee in accordance with the terms of this Program. 

(c) Designated Participants. The Program’s Designated Participants were approved by the Committee on
November 5, 2014 and are as specified on APPENDIX B. Except as provided in this Program, no Employee has any right (i) to be a Designated Participant in the Program, (ii) to continue as a Designated Participant,
or (iii) to be granted a potential Maximum Award or to earn an Actual Award under the Program. 
 (d)
Performance Goals and Performance Period. Actual Award amounts will be calculated based upon the Committee’s determination of the Company’s level of attainment of the Performance Goals during the Performance Period
pursuant to the following criteria: 
 (i) The Actual Award amount will be calculated based on the TSR from
November 5, 2014 to May 6, 2015 (the “Measurement Period”). VWAP will be used to calculate the TSR. In order for any Actual Award to be earned under the Program, the TSR during the Measurement Period must be greater
than or equal to 15% (the “Measurement Period Threshold Goal”) or a Change in Control must occur prior to expiration of the Measurement Period. The VWAP on November 5, 2014 was $12.08, so the minimum VWAP that is
required on May 6, 2015 for the Measurement Period Threshold Goal to be attained is $12.95 (assuming no dividends or distributions are made or declared in respect of the Company’s ordinary shares during the Measurement Period). If the VWAP
on May 6, 2015 is less than $12.95, no Actual Awards will be paid under the Program and the Program will immediately terminate following completion of the Measurement Period without payment to any Designated Participant (unless a Change in
Control occurs prior to expiration of the Measurement Period). 

  
 1 

 (ii) If the Measurement Period Threshold Goal is attained, the determined
Actual Award amount for each Designated Participant will correspond to the applicable corresponding award level set forth on the schedule on the attached APPENDIX B for such Designated Participant based upon the percentage
of TSR attained during the Measurement Period as determined pursuant to the table below (assuming no dividends or distributions are made or declared in respect of the Company’s ordinary shares during the Measurement Period): 

 

			
	 TSR from 11/5/14 to 5/6/15
	  	 VWAP on 5/6/15

	 Less than 15%
	  	< $12.95
	 3 15% and < 25%
	  	3 $12.95 and £ $13.50
	 3 25% and < 40%
	  	3 $13.51 and £ $14.28
	 3 40% and < 60%
	  	3 $14.29 and £ $15.27
	 3 60%
	  	3 $15.28

 provided, however, that if a Change in Control occurs before expiration of the Measurement Period, for
purposes of calculating Actual Awards, the TSR will be deemed to have been greater than 60% during the Measurement Period so that the determined Actual Award amount will equal the Maximum Award set forth on APPENDIX B. 

(iii) Any Designated Participant who switches from full-time to part-time employment during the Measurement Period will
have his or her Actual Award reduced on a pro-rata basis based upon the applicable percentage of full-time equivalent employment that was in effect on an aggregate basis during the Measurement Period. For the avoidance of doubt, no adjustment will
be made to the determined amount of an Actual Award for any Designated Participant due to any reduction in the percentage of full-time equivalent employment of a Designated Participant that occurs after expiration of the Measurement Period and prior
to expiration of the Performance Period. 
 (iv) The determined Actual Award amount will become earned by and payable
to a Designated Participant subject to (A) attainment of the Performance Period Threshold Goal upon the completion of the Performance Period or the occurrence of a Change in Control prior to the expiration of the Performance Period and
(B) the Designated Participant’s satisfaction of the Continuous Service requirements set forth in Section 2(e) below. VWAP will be used on each measurement date to calculate the TSR of the Company’s ordinary shares during the
Performance Period in order to determine whether the Performance Period Threshold Goal has been attained. The VWAP on November 5, 2014 was $12.08, so the minimum VWAP on November 4, 2017 that is required for the Performance Period
Threshold Goal to be attained is $18.37 (assuming no dividends or distributions are made or declared in respect of the Company’s ordinary shares during the Performance Period). If a Change in Control does not occur prior to expiration of the
Performance Period and the VWAP on November 4, 2017 is less than $18.37 so that the Performance Period Threshold Goal is not attained, no Actual Award will be payable under the Program so that the Program will automatically terminate without
payment to any Designated Participant. 
 (e) Continuous Service.  

(i) Except as otherwise provided below in Section 2(e)(ii) or 2(e)(iii), in order to earn an Actual Award under the
Program, a Designated Participant must remain in Continuous Service through the expiration of the Performance Period. Except as otherwise provided below in Section 2(e)(ii) or 2(e)(iii), if a Designated Participant terminates Continuous Service
for any reason prior to the expiration of the Performance Period, the Designated Participant will forfeit the right to any payment under the Program and will not earn an Actual Award. 

(ii) If prior to the expiration of the Performance Period, a Designated Participant terminates Continuous Service due to
either (A) a termination by the Company without Cause, or (B) the 

  
 2 

 
Designated Participant’s death or Disability and the Designated Participant or his or her beneficiaries (as applicable) provide the Company and its Affiliates with an effective release of
claims in a form acceptable to the Company (the “Release”) no later than the earlier of: (i) December 31, 2017, or (ii) fifty five (55) days following a Change in Control that occurs prior to the
expiration of the Performance Period, the Designated Participant will still be eligible to earn an Actual Award subject to the Company’s attainment of the Performance Goals during the Performance Period or the earlier occurrence of a Change in
Control. If Plan payments are to be made in connection with a Change in Control event and the Release could become effective in more than one taxable year depending on the timing of provision, the Release will not be deemed effective until the
latest taxable year in which it could be effective. In no event will Plan payments be made prior to the effectiveness (or deemed effectiveness) of the Release. 

(iii) All Designated Participants who remain in Continuous Service through the date of a Change in Control that occurs
prior to the expiration of the Performance Period will have earned an Actual Award. 
 3. Other Program Provisions. 

(a) Determination and Payment of Actual Awards. Assessment of actual performance, determination of the
Actual Awards and any payment in respect of Actual Awards will be subject to: (i) the Committee’s certification in writing that the applicable Performance Goals and other terms of the Program have been met; provided, however, that such
certification requirement shall not be applicable in the event of a Change in Control that occurs prior to expiration of the Performance Period. All Actual Awards which are earned under the Program will be paid to Designated Participants as soon as
administratively practicable following expiration of the Performance Period but in no event later than December 31, 2017; provided however that if a Change in Control occurs during the Performance Period, Actual Awards earned under the Program
will be paid to Designated Participants as soon as practicable but in no event later than sixty (60) days following the Change in Control. 

(b) Withholding. The Company will withhold from payment of any Actual Award an amount in satisfaction of
any federal, state or local tax withholding obligation relating to the payment of the Actual Award as necessary to satisfy the Company’s required tax withholding obligations using the minimum statutory withholding rates for federal, state,
local and foreign tax purposes, including payroll taxes, that are applicable to supplemental taxable income. 
 (c)
No Employment or Service Rights. Nothing in the Program or any instrument executed pursuant to the Program will (i) confer upon any Designated Participant any right to continue to be retained in the employ or service of the
Company or any other Affiliate, (ii) change the at-will employment relationship between the Company or any other Affiliate and a Designated Participant, or (iii) interfere with the right of the Company or any other Affiliate to discharge
any Designated Participant or other person at any time, with or without Cause, and with or without advance notice. 
 (d)
Program Administration. The Committee will be responsible for all decisions and recommendations regarding Program administration and retains final authority regarding all aspects of Program administration, interpretation of the
Program, the resolution of any disputes, and application of the Program in any respect to a Designated Participant. All determinations and interpretations made by the Committee in good faith will not be subject to review by any person and will be
final, binding and conclusive on all persons. The Committee may, without notice, amend, suspend or terminate the Program; provided, however, that no such action may adversely affect any Designated Participant unless (i) expressly
provided by the Committee; and (ii) with the consent of the Designated Participant, unless such action is necessary to comply with any applicable law, regulation or rule. 

(e) Recovery. Any amounts paid under the Program will be subject to recoupment in accordance with
any clawback policy that the Company adopts pursuant to the listing standards of any national 

  
 3 

 
securities exchange or association on which the Company’s securities are listed or as is otherwise adopted pursuant to the Dodd-Frank Wall Street Reform and Consumer Protection Act or other
applicable law. No recovery of compensation under such a clawback policy will be an event giving rise to a right to resign for “good reason” or “constructive termination” (or similar term) under any plan of or agreement with the
Company. 
 (f) Validity. If any provision of the Program is held invalid, void, or unenforceable, the
same will not affect, in any respect whatsoever, the validity of any other provision of the Program. 
 (g)
Section 409A. All Program payments are intended to satisfy the requirements for an exemption from application of Section 409A provided under Treasury Regulations Sections 1.409A-1(b)(4) to the maximum extent such
exemption is available. To the extent Program payments are subject to Section 409A, Program payments are intended to be paid on the earlier of a “specified date” or upon a Change in Control in compliance with the requirements of
Section 409A. Program payments are intended to qualify for an exemption from application of Section 409A or comply with its requirements to the extent necessary to avoid adverse personal tax consequences to the Designated Participants
under Section 409A, and any ambiguities herein shall be interpreted accordingly. 
 (h) Governing Plan
Document. The Program is subject to all the provisions of the Equity Incentive Plan and is further subject to all interpretations, amendments, rules and regulations that may from time to time be promulgated and adopted by the
Committee, the Board or the Company pursuant to the Equity Incentive Plan. In the event of any conflict between the provisions of this Program and those of the Equity Incentive Plan, the provisions of the Equity Incentive Plan will control unless
necessary for compliance with Section 162(m) of the Code or as necessary to avoid adverse personal tax consequences to the Designated Participants under Section 409A. 

  
 4 

 APPENDIX A 

CASH LONG TERM INCENTIVE PROGRAM 

DEFINITIONS 

(a) “Actual Award” means the amount of cash bonus awarded to a Designated Participant under the
Program based on the Committee’s determination of the level of achievement of the Performance Goals during the Measurement Period and the Performance Period. 

(b) “Cause” for the Company or an Affiliate to terminate a Designated Participant’s
employment shall mean the occurrence of any of the following events, as determined reasonably and in good faith by the Committee: 

(1) the Designated Participant’s gross negligence or willful failure to substantially perform his duties and
responsibilities to the Company or Affiliate or willful and deliberate violation of a Company or Affiliate policy; 
 (2)
the Designated Participant’s conviction of a felony or the Designated Participant’s commission of any act of fraud, embezzlement or dishonesty against the Company or Affiliate or involving moral turpitude that is likely to inflict or
has inflicted material injury on the business of the Company or an Affiliate, to be determined by the sole discretion of the Committee; 

(3) the Designated Participant’s unauthorized use or disclosure of any proprietary information or trade secrets of
the Company or an Affiliate or any other party that the Designated Participant’ owes an obligation of nondisclosure as a result of the Designated Participant’s relationship with the Company or an Affiliate; and 

(4) the Designated Participant’s willful and deliberate breach of any employment obligations that causes material
injury to the business of the Company or an Affiliate. 
 (c) “Certification Date” means the
date on which the Committee certifies whether the Performance Goals have been met under the Program. The Certification Date will be no later than December 15, 2017. 

(d) “Change in Control” means the first to occur of (1) a change in the ownership of the
Company, (2) a change in the effective control of the Company or (3) a change in the ownership of a substantial portion of the Company’s assets as specified below. For such purposes, a change in ownership of the Company occurs on the
date on which any one person or more than one person acting as a group acquires ownership of shares of the Company that, together with shares held by such person or group constitutes more than 50% of the total fair market value or total voting power
of the shares of the Company. A change in the effective control of the Company occurs on the date on which either (i) a person or more than one person acting as a group acquires during any 12-month period ownership of shares of the Company
possessing 50% or more of the total voting power of the shares of the Company or (ii) a majority of members of the Company’s board of directors is replaced during any 12-month period by directors whose appointment or election is not
endorsed by a majority of the members of the Company’s board of directors prior to the date of the appointment or election. A change in the ownership of a substantial portion of assets occurs on the date on which any one person or more than one
person acting as a group acquires assets from the Company that have a total gross fair market value equal to or more than 75% of the total gross fair market value of all of the assets of the Company immediately prior to such acquisition or
acquisitions. The determination of whether a Change in Control has occurred will be determined in a manner consistent with the requirements of Section 409A. 

(e) “Committee” means the Compensation Committee of the Board of Directors. 

 (f) “Disability” means the Designated Participant
is unable to engage in any substantial gainful activity by reason of any medically determinable physical or mental impairment which can be expected to result in death or can be expected to last for a continuous period of not less than 12 months, or
is, by reason of any medically determinable physical or mental impairment which can be expected to result in death or can be expected to last for a continuous period of not less than 12 months, receiving income replacement benefits for a period of
not less than three months under an accident and health plan covering Company employees. The determination of whether a Designated Participant has incurred a Disability will be determined in a manner consistent with the requirements of
Section 409A. 
 (g) “Equity Incentive Plan” means the Horizon Pharma Public Limited
Company 2014 Equity Incentive Plan, as may be amended. 
 (h) “Performance Period Threshold
Goal” means the TSR, if any, during the Performance Period which is greater than or equal to 15%. 
 (i)
“Section 409A” means Section 409A of the Internal Revenue Code of 1986, as amended from time to time, including regulations and other guidance thereunder, and any state law of similar effect. 

(j) “TSR” means the percentage change in the price of the Company’s ordinary shares on a
compounded annualized basis plus the dollar value of dividends and distributions made or declared divided by the closing price of the Company’s ordinary shares on the record date of the dividends and distributions. 

(k) “VWAP” means the trailing 20-trading-day volume weighted average price of the Company’s
ordinary shares as reported on Nasdaq.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00240-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00240-of-00352.parquet"}]]